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Developing Cell Carriers for Delivering Cells from the Laboratory to the Clinic 
 Clinical and Commercial Experiences 
 
Sheila MacNeil 




My group began culturing sheets of autologous keratinocytes for the treatment of burns patients in 1992, 
working with local burns surgeons in Sheffield (1).  An analysis of the difficulties of producing these sheets so 
that their production matched the needs of the patients, led to the development of an alternative simpler 
technology for transferring cells from the laboratory to the clinic, that of using an engineered surface (plasma 
polymerised acrylic acid).  This was commercialised through a University of Sheffield spin out company, CellTran 
Ltd.  During the 8 years that CellTran ran, 2000-2008, it produced two products approved for clinical use for the 
treatment of patients with burns and chronic non-healing wounds  Myskin, autologous keratinocytes on a 
carrier dressing, and Cryoskin, allogeneic keratinocytes available from frozen on a carrier dressing. We published 
a single blind study showing the efficacy of this cell therapy for the acceleration of healing of chronic non-healing 
neuropathic diabetic ulcers (2).  MySkin has been commercially available in the UK since 2004 for NHS patients 
suffering from severe burns and chronic non-healing ulcers and is now produced by the company Regenerys Ltd.   
  
The same approach of delivering cells on carrier dressings was then extended to developing surfaces for delivery 
of corneal epithelial cells (3)  human melanocytes and keratinocytes (for the treatment of patients with vitiligo 
or hypopigmentation following burns injury) (4) and more recently for the delivery of bone marrow MSC cells 
for the treatment of chronic wounds (5,6). 
  
The above approaches to delivering cells from the laboratory to patients who may be geographically distant 
from the cell culture facility require that cells can travel for several days and still be fit for purpose on their 
arrival. This is an important step in translating cell therapy to enable many patients to benefit from this therapy.  
  
Beyond this in an international collaboration with India funded by the Wellcome Trust our group has developed 
a synthetic biodegradable carrier for assisting surgeons in cornea regeneration.  Patients can lose the specialist 
limbal stem cells which provide the clear cornea for a variety of reasons  trauma, genetic diseases or immune 
conditions.  Once these cells are lost the cells which rush in to cover the cornea are essentially scar tissue and 
this results in loss of vision for the patient.  Currently some 12 specialist centres worldwide culture limbal 
epithelial stem cells in the laboratory (usually taking cells from the good eye to treat the opposite scarred eye 
when the condition is unilateral). To assist the cells to survive on the eyes, cells are transplanted back on human 
amniotic membrane.  This is a donor human tissue with inherent risks of viral disease transmission and its also 
variable and not everyone has access to amniotic membrane.   
  
Our group has developed an electrospun biodegradable membrane made of polylactic acid and we have shown 
that it can be combined not only with cultured cells (expanded under clean room conditions) but also with small 
tissue explants held in place with fibrin glue.  Both lead to regeneration of a multi-layered corneal epithelium in 
vitro.  Working with our colleagues in India we have now obtained regulatory approval to do a first in man study 
in India taking small explants of the unaffected eye, placing these on the biodegradable membrane held in place 
with fibrin and putting the membrane on the eye.   
  
So not only will the synthetic membrane be safer it offers the potential to greatly simplify the process of treating 
these patients , making the therapy much more accessible to ophthalmic centres worldwide without the need 
for specialist clean rooms for the culture of cells or access to tissue bank for amniotic membrane.  This should 
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